Cabot Corporation (NYSE:CBT) Given Consensus Recommendation of "Hold" by Brokerages

Cabot Corporation (NYSE:CBT - Get Free Report) has been assigned an average recommendation of "Hold" from the seven analysts that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have issued a buy recommendation on the company. The average 1-year target price among brokers that have updated their coverage on the stock in the last year is $89.00.

CBT has been the topic of several recent analyst reports. UBS Group cut their target price on Cabot from $97.00 to $92.00 and set a "neutral" rating on the stock in a research note on Wednesday, August 5th. Weiss Ratings reiterated a "hold (c)" rating on shares of Cabot in a research note on Friday, August 21st. Mizuho increased their price objective on shares of Cabot from $80.00 to $90.00 and gave the company a "neutral" rating in a research report on Thursday, June 25th. JPMorgan Chase & Co. boosted their price objective on shares of Cabot from $70.00 to $78.00 and gave the company an "underweight" rating in a report on Friday, August 7th. Finally, Truist Financial set a $100.00 price target on shares of Cabot in a research report on Wednesday, August 5th.

Cabot Stock Down 0.0%

Shares of NYSE:CBT opened at $81.47 on Monday. The stock's 50-day moving average price is $86.67 and its 200-day moving average price is $81.44. The company has a current ratio of 1.47, a quick ratio of 0.97 and a debt-to-equity ratio of 0.48. Cabot has a 12-month low of $58.33 and a 12-month high of $94.53. The stock has a market capitalization of $4.21 billion, a P/E ratio of 22.95, a price-to-earnings-growth ratio of 10.70 and a beta of 0.83.

Cabot (NYSE:CBT - Get Free Report) last announced its quarterly earnings results on Monday, August 3rd. The specialty chemicals company reported $1.67 EPS for the quarter, topping analysts' consensus estimates of $1.66 by $0.01. Cabot had a return on equity of 20.29% and a net margin of 5.23%.The business had revenue of $982.00 million for the quarter, compared to analysts' expectations of $943.16 million. During the same period in the previous year, the firm earned $1.90 EPS. The business's quarterly revenue was up 6.4% on a year-over-year basis. Cabot has set its FY 2026 guidance at 6.150-6.450 EPS. On average, equities analysts anticipate that Cabot will post 6.35 earnings per share for the current year.

Cabot Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 28th will be issued a $0.4725 dividend. The ex-dividend date of this dividend is Friday, August 28th. This represents a $1.89 annualized dividend and a yield of 2.3%. Cabot's dividend payout ratio is currently 53.24%.

Insider Activity

In other Cabot news, CEO Sean Keohane sold 134,895 shares of the company's stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $85.00, for a total value of $11,466,075.00. Following the completion of the transaction, the chief executive officer directly owned 404,134 shares in the company, valued at $34,351,390. This represents a 25.03% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders sold a total of 229,597 shares of company stock worth $19,646,746 in the last three months. Company insiders own 3.08% of the company's stock.

Hedge Funds Weigh In On Cabot

Several institutional investors have recently bought and sold shares of CBT. Rothschild Investment LLC grew its position in shares of Cabot by 170.4% during the fourth quarter. Rothschild Investment LLC now owns 411 shares of the specialty chemicals company's stock valued at $27,000 after purchasing an additional 259 shares in the last quarter. Northwestern Mutual Wealth Management Co. bought a new stake in shares of Cabot in the 2nd quarter worth about $33,000. Global Retirement Partners LLC boosted its stake in shares of Cabot by 1,606.9% during the 4th quarter. Global Retirement Partners LLC now owns 495 shares of the specialty chemicals company's stock worth $33,000 after purchasing an additional 466 shares during the period. Geneos Wealth Management Inc. boosted its stake in shares of Cabot by 409.0% during the 1st quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company's stock worth $38,000 after purchasing an additional 364 shares during the period. Finally, Danske Bank A S bought a new stake in shares of Cabot during the 3rd quarter worth approximately $38,000. 93.18% of the stock is owned by hedge funds and other institutional investors.

Cabot Company Profile

Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.

The company operates two primary segments: Reinforcement Materials and Performance Materials.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source